ALAR PHARMACEUTICALS INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Different from the current long-acting technologies, drug products developed by our unique long-acting release platform (In-Relar) have distinctive characteristics such as low viscosity solution, small injection volume, and sustained drug release profile,
The content above was translated by Ai
Founded Year
2016
Unified Business No.
52310651
Status
Active
Number of Employees
0
Total Paid-in
Capital
668,000,000 (NT$)
Location of Company
Taiwan
, Taichung City
Exit Status
OTC listing(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Alar Pharmaceuticals Inc., established in 2016, is a new drug development company focusing on developing long-acting release drug products for CNS disorders and chronic diseases. Aiming to submit the new drug application via the 505(b)(2) regulatory pathway and address the unmet medical needs, long-acting injectables for treating opioid use disorder, chronic pain, treatment-resistant depression, and other diseases are under development. Long-acting release products could not only relieve the burden of daily medication, enhance patient’s compliance, and increase drug adherence, but could also improve medical quality and have greater potential to achieve treatment success.
The content above was translated by Ai
